Tourmaline Bio, Inc.
Tourmaline Bio, Inc. (TRML) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
trml · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Tourmaline Bio, Inc. (TRML) measures how much investors pay for each dollar of the company's trailing earnings. TRML's current PE ratio of N/A is calculated by dividing its stock price of $47.98 by its TTM earnings per share of -$2.65.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2019 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Tourmaline Bio, Inc.You TRML | $1.2B | N/A | — | -$2.65 |
 Amylyx Pharmaceuticals, Inc. AMLX | $1.1B | N/A | — | -$1.53 |
 Dianthus Therapeutics, Inc. DNTH | $3.4B | N/A | — | -$4.30 |
 Enliven Therapeutics, Inc. ELVN | $2.0B | N/A | — | -$1.83 |
 Immatics N.V. IMTX | $1.2B | N/A | — | -$1.61 |
 ORIC Pharmaceuticals, Inc. ORIC | $779M | N/A | — | -$1.47 |
 Precigen, Inc. PGEN | $1.1B | N/A | — | -$0.82 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-2.89 | — | |
2023-12-31 FY2023 | — | $-8.87 | — | |
2022-12-31 FY2022 | — | $-0.97 | — | |
2021-12-31 FY2021 | — | $-0.00 | — | |
2020-12-31 FY2020 | — | $-33.97 | — | |
2019-12-31 FY2019 | — | $-4.39 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Tourmaline Bio, Inc. (TRML) measures how much investors pay for each dollar of the company's trailing earnings. TRML's current PE ratio of N/A is calculated by dividing its stock price of $47.98 by its TTM earnings per share of -$2.65.
Frequently asked questions
TRML pe ratio · 6 questionsTRML's current PE ratio is N/A as of 2026-06-08, based on a stock price of $47.98 and TTM EPS of -$2.65. Data sourced from Financial Modeling Prep via TRML's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Tourmaline Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08